|1.||Hasanein, Parisa: 2 articles (05/2011 - 09/2010)|
|2.||Rahimi-Balaei, Maryam: 1 article (12/2015)|
|3.||Shirzadian, Armin: 1 article (12/2015)|
|4.||Hassanipour, Mahsa: 1 article (12/2015)|
|5.||Amiri, Shayan: 1 article (12/2015)|
|6.||Amini-Khoei, Hossein: 1 article (12/2015)|
|7.||Mehr, Shahram Ejtemaie: 1 article (12/2015)|
|8.||Dehpour, Ahmad Reza: 1 article (12/2015)|
|9.||Gooshe, Maziar: 1 article (12/2015)|
|10.||Haj-Mirzaian, Arya: 1 article (12/2015)|
05/01/2011 - "The results indicated the efficacy of immepip systemic administration in an experimental model of diabetic hyperalgesia. "
05/01/2011 - "5 and 30 mg/kg doses of immepip reversed chemical hyperalgesia in diabetic rats. "
05/01/2011 - "In this study, the efficacy of systemic administration of selective H3 receptor agonist, immepip (1, 5 and 30 mg/kg), and antagonist, thioperamide (5, 15 and 30 mg/kg), was investigated on hyperalgesia during the formalin test in streptozocin (STZ)-induced diabetic rats. "
05/01/2011 - "The 1 mg dose of immepip did not alter pain behaviors in control and diabetic groups compared to the respective control ones. "
03/01/2005 - "In addition, immepip (5 mg/kg, subcutaneous) significantly attenuated formalin-induced flinching, but not formalin-induced licking, during both phase 1 and phase 2, suggesting that H 3 agonists might be effective in treating some forms of clinically relevant pain. "
|4.||Body Weight (Weight, Body)
10/15/2014 - "The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats."
06/01/2006 - "Coadministration of immepip (1 mg/kg) with L-dopa (15 mg/kg) was associated with significantly less total dyskinesia than L-dopa alone. "
06/01/2006 - "When dyskinesia was separately rated as chorea and dystonia, coadministration of L-dopa with either immepip or imetit (both 10 mg/kg) significantly reduced chorea but had no effect on dystonia. "
10/15/2014 - "In the MPTP-treated common marmoset exhibiting dyskinesia to l-dopa, immepip alone induced retching and in combination with l-dopa administered subcutaneously or orally induced the rapid onset of retching and vomiting which was not controlled by pretreatment with domperidone. "
10/15/2014 - "We examined the effects of the H3 agonist, immepip, in 6-OHDA-lesioned rats exhibiting AIMs (abnormal involuntary movements), a rat analogue of dyskinesia, in response to l-dopa compared to the known anti-dyskinetic agents amantadine, MK-801 and 8-OHDPAT. "
|4.||Histamine (Histamine Dihydrochloride)
|7.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|8.||Levodopa (L Dopa)
|9.||Dizocilpine Maleate (Dizocilpine)